



## Editorial Molecular Mechanisms of Animal Toxins, Venoms and Antivenoms

R. Manjunatha Kini <sup>1</sup> and Yuri N. Utkin <sup>2,\*</sup>

- <sup>1</sup> Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore; dbskinim@nus.edu.sg
- <sup>2</sup> Laboratory of Molecular Toxinology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, 117997 Moscow, Russia
- \* Correspondence: utkin@ibch.ru or yutkin@yandex.ru; Tel.: +7-495-3366522

In many animals belonging to different taxa, venoms evolved as a means of defense and/or a means of attack/hunting. Venoms contain compounds of various chemical natures, usually called toxins. Over the course of evolution, toxins have acquired the ability to affect different systems in the organisms of prey, victims and predators. Usually, a single venom contains a large array of toxins directed against multiple biological targets. Depending on the species of the venomous animal, this array varies greatly. Toxins affect practically all vitally important systems in living organisms. Thus, in the nerve system, neurotoxins influence different stages of nerve impulse transmission [1,2], and in the cardiovascular system, toxins affect the heart, blood vessels and blood coagulation. The effects of some animal toxins result in muscle degradation [3]. The immune system is also influenced by these toxins; for example, complement is depleted by the cobra venom factor [4]. The manuscripts submitted to this Special Issue uncover the molecular mechanisms of animal toxin effects on the cardiovascular [5] and immune [6] systems.

The development of methods for the identification and analysis of the chemical structure of organic compounds [7] leads to the discovery of new toxins, for which it is necessary to establish the mechanisms of action. The work of Van Baelen et al. [8] published in this Special Issue is an example of the discovery of an animal toxin with new biological activity. Moreover, new species of venomous animals are being discovered, for which it is also necessary to establish the venom profiles and molecular mechanisms of venom action. Thus, mammalian representatives, including the platypus [9] and slow lorises [10], have recently been added to the animals traditionally considered venomous, such as snakes, scorpions and spiders.

Because animal toxins have evolved to interact with specific biological targets with high efficiency and selectivity, they are widely used as research tools. First,  $\alpha$ -bungarotoxin from the venom of the krait *Bungarus multicinctus* should be mentioned [11]. The discovery of this toxin greatly contributed to the establishment of the molecular mechanisms of nerve impulse transduction [12]. Due to their high efficiency and selectivity of action, animal toxins are considered a promising basis for the creation of new drugs (e.g., [13,14]). However, despite numerous studies, the number of drugs used that are based on these toxins is currently quite limited [15].

Although not all animal venoms and toxins are dangerous to humans, the problem of treating bites from venomous animals remains a significant problem in a number of world regions [16]. Understanding the action mechanisms of animal venoms is very important for the effective treatment of intoxication by venomous animals. Currently, the most effective way to treat bites from venomous animals is the use of antisera, which is obtained by immunizing large mammals (mainly horses) with small doses of venom [17,18]. Although very effective, this method has several disadvantages and requires the development of new treatments based on other molecular mechanisms [19,20]. Without knowledge of the structures of toxins and their biological effects, this development is hardly possible.



Citation: Kini, R.M.; Utkin, Y.N. Molecular Mechanisms of Animal Toxins, Venoms and Antivenoms. *Int. J. Mol. Sci.* 2023, 24, 16389. https:// doi.org/10.3390/ijms242216389

Received: 4 November 2023 Accepted: 8 November 2023 Published: 16 November 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). All of the above factors dictate the need to study the structure and mechanisms of action of both animal toxins and venoms, as a source of new toxins.

Author Contributions: Writing—original draft preparation, R.M.K. and Y.N.U.; writing—review and editing, R.M.K. and Y.N.U. All authors have read and agreed to the published version of the manuscript.

**Funding:** The work of Y.N.U. on this paper was funded by the Russian Science Foundation, grant number 21-14-00316.

Conflicts of Interest: The authors declare no conflict of interest.

## References

- Zhou, K.; Luo, W.; Liu, T.; Ni, Y.; Qin, Z. Neurotoxins Acting at Synaptic Sites: A Brief Review on Mechanisms and Clinical Applications. *Toxins* 2022, 15, 18. [CrossRef] [PubMed]
- Mackieh, R.; Abou-Nader, R.; Wehbe, R.; Mattei, C.; Legros, C.; Fajloun, Z.; Sabatier, J.M. Voltage-Gated Sodium Channels: A Prominent Target of Marine Toxins. *Mar. Drugs* 2021, 19, 562. [CrossRef] [PubMed]
- Lomonte, B. Lys49 myotoxins, secreted phospholipase A2-like proteins of viperid venoms: A comprehensive review. *Toxicon* 2023, 224, 107024. [CrossRef] [PubMed]
- 4. Vogel, C.W.; Fritzinger, D.C. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion. *Toxicon* **2010**, *56*, 1198–1222. [CrossRef] [PubMed]
- Averin, A.S.; Berezhnov, A.V.; Pimenov, O.Y.; Galimova, M.H.; Starkov, V.G.; Tsetlin, V.I.; Utkin, Y.N. Effects of Cobra Cardiotoxins on Intracellular Calcium and the Contracture of Rat Cardiomyocytes Depend on Their Structural Types. *Int. J. Mol. Sci.* 2023, 24, 9259. [CrossRef] [PubMed]
- Gabrili, J.J.M.; Villas-Boas, I.M.; Pidde, G.; Squaiella-Baptistão, C.C.; Woodruff, T.M.; Tambourgi, D.V. Complement System Inhibition Modulates the Inflammation Induced by the Venom of Premolis semirufa, an Amazon Rainforest Moth Caterpillar. *Int. J. Mol. Sci.* 2022, 23, 13333. [CrossRef] [PubMed]
- Abd El-Aziz, T.M.; Soares, A.G.; Stockand, J.D. Advances in venomics: Modern separation techniques and mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2020, 1160, 122352. [CrossRef] [PubMed]
- 8. Van Baelen, A.-C.; Iturrioz, X.; Chaigneau, M.; Kessler, P.; Llorens-Cortes, C.; Servent, D.; Gilles, N.; Robin, P. Characterization of the First Animal Toxin Acting as an Antagonist on AT1 Receptor. *Int. J. Mol. Sci.* **2023**, *24*, 2330. [CrossRef] [PubMed]
- Wong, E.S.; Morgenstern, D.; Mofiz, E.; Gombert, S.; Morris, K.M.; Temple-Smith, P.; Renfree, M.B.; Whittington, C.M.; King, G.F.; Warren, W.C.; et al. Proteomics and deep sequencing comparison of seasonally active venom glands in the platypus reveals novel venom peptides and distinct expression profiles. *Mol. Cell Proteom.* 2012, *11*, 1354–1364. [CrossRef] [PubMed]
- 10. Nekaris, K.A.I.; Campera, M.; Nijman, V.; Birot, H.; Rode-Margono, E.J.; Fry, B.G.; Weldon, A.; Wirdateti, W.; Imron, M.A. Slow lorises use venom as a weapon in intraspecific competition. *Curr. Biol.* **2020**, *30*, R1252–R1253. [CrossRef] [PubMed]
- Chang, C.C.; Lee, C.Y. Isolation of Neurotoxins from the Venom of Bungarus Multicinctus and Their Modes of Neuromuscular Blocking Action. Arch. Int. Pharmacodyn. Ther. 1963, 144, 241–257. [PubMed]
- 12. Nirthanan, S. Snake three-finger α-neurotoxins and nicotinic acetylcholine receptors: Molecules, mechanisms and medicine. *Biochem. Pharmacol.* **2020**, *181*, 114168. [CrossRef] [PubMed]
- 13. Oliveira, A.L.; Viegas, M.F.; da Silva, S.L.; Soares, A.M.; Ramos, M.J.; Fernandes, P.A. The chemistry of snake venom and its medicinal potential. *Nat. Rev. Chem.* 2022, *6*, 451–469. [CrossRef] [PubMed]
- Bordon, K.C.F.; Cologna, C.T.; Fornari-Baldo, E.C.; Pinheiro-Júnior, E.L.; Cerni, F.A.; Amorim, F.G.; Anjolette, F.A.P.; Cordeiro, F.A.; Wiezel, G.A.; Cardoso, I.A.; et al. From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery. *Front. Pharmacol.* 2020, *11*, 1132. [CrossRef] [PubMed]
- Clark, G.C.; Casewell, N.R.; Elliott, C.T.; Harvey, A.L.; Jamieson, A.G.; Strong, P.N.; Turner, A.D. Friends or Foes? Emerging Impacts of Biological Toxins. *Trends Biochem. Sci.* 2019, 44, 365–379. [CrossRef] [PubMed]
- 16. Seifert, S.A.; Armitage, J.O.; Sanchez, E.E. Snake Envenomation. N. Engl. J. Med. 2022, 386, 68–78. [CrossRef] [PubMed]
- 17. Ratanabanangkoon, K. Polyvalent Snake Antivenoms: Production Strategy and Their Therapeutic Benefits. *Toxins* **2023**, *15*, 517. [CrossRef]
- Rathore, A.S.; Kumar, R.; Tiwari, O.S. Recent advancements in snake antivenom production. *Int. J. Biol. Macromol.* 2023, 240, 124478. [CrossRef] [PubMed]

- 19. Vanuopadath, M.; Rajan, K.; Alangode, A.; Nair, S.S.; Nair, B.G. The Need for Next-Generation Antivenom for Snakebite Envenomation in India. *Toxins* 2023, *15*, 510. [CrossRef] [PubMed]
- Alonso Villela, S.M.; Kraïem-Ghezal, H.; Bouhaouala-Zahar, B.; Bideaux, C.; Aceves Lara, C.A.; Fillaudeau, L. Production of recombinant scorpion antivenoms in E. coli: Current state and perspectives. *Appl. Microbiol. Biotechnol.* 2023, 107, 4133–4152. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.